MedTrace Logo

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

NCT01447043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2609

Last updated 2014-01-27

No results posted yet for this study

Summary

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

Conditions

  • Ophthalmology, Macular Degeneration

Interventions

DRUG

Ranibizumab

Patients with wet AMD treated with ranibizumab as prescribed by physician

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-08-31
Completion
2012-11-30

Countries

  • Australia
  • Canada
  • France
  • Germany
  • Ireland
  • Italy
  • Japan
  • Netherlands
  • United Kingdom
  • Venezuela

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01447043 on ClinicalTrials.gov